查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
大分子CDMO市場規模、份額、趨勢分析報告:按服務（合同製造、合同開發）、供應商、最終用戶、地區、細分市場，2023-2030 年
市場調查報告書
商品編碼
1171057

大分子CDMO市場規模、份額、趨勢分析報告:按服務（合同製造、合同開發）、供應商、最終用戶、地區、細分市場，2023-2030 年

Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Service (Contract Manufacturing, Contract Development), By Source, By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 145 Pages | 商品交期: 2-10個工作天內

價格

大分子藥物CDMO的市場增長及趨勢

到 2030 年，全球大分子 CDMO 市場規模預計將達到 221 億美元，2023 年至 2030 年的複合年增長率為 9.3%。 傳染病發病率上升和對新型治療藥物的高需求是推動市場的主要因素。

合同製造是大分子藥物製造的關鍵步驟之一，佔大分子藥物市場的很大一部分。 製造形式是一個需要考慮的重要因素，因為它代表了該領域的外包或內部活動。 由於高成本和時間延遲，公司現在選擇外包服務。 因此，公司將大部分大分子外包出去。 CDMO（合同開發和製造組織）是一家為製藥行業提供從藥物開發到製造的綜合服務的公司。 CDMO 通過引入第三方項目並提供他們的知識、開發和製造能力來提供重要服務。

在 COVID-19 大流行之前，大量新的治療方案導致對大分子藥物的投資增加。 在開發針對 SARS-CoV-2 病毒的療法和疫苗的競賽中，出現了對生物製劑的評估。 特別是CDMOs對大批量、高質量CGMP原料藥和藥品生產服務的需求急劇增加，CDMOs可以提供廣泛的COVID疫苗技術和治療性單克隆抗體產品。

大分子 CDMO 市場報告要點

到2022年，合同製造服務領域將以超過65.0%的銷售額佔據市場主導地位

按供應來源劃分，2022 年哺乳動物部分佔比最大，超過 55.0%。 隨著更複雜的生物製劑的發展，例如雙特異性和三特異性抗體以及抗體-藥物偶聯物，這一類別將擴大。

到 2022 年，按最終用戶劃分，生物技術公司將佔據最大份額，超過 40.0%。 企業加大大分子研發投入驅動市場

亞太地區預計在預測期內實現 10.4% 的複合年增長率最快。 高患者人數、低成本、熟練勞動力和不斷變化的監管情景是市場擴張的主要驅動力

內容

第1章調查方法及範圍

  • 市場細分和範圍
    • 服務
    • 來源
    • 最終用戶
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的詳細信息
      • 來自北美主要訪談的數據
      • 來自歐洲主要訪談的數據
      • 來自亞太地區主要訪談的數據
      • 來自拉丁美洲主要訪談的數據
      • 來自關於 Mea 的主要訪談的數據
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析（模型 1）
      • 方法 1:商品流方法
    • 批量價格分析（模型 2）
      • 方法 2:量價分析
  • 二級信息列表
  • 主要信息列表
  • 縮寫列表

第 2 章執行摘要

  • 市場前景

第 3 章大分子 CDMO 市場:變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
    • 輔助市場展望
  • 市場變量分析
    • 市場驅動因素分析
      • 增加對大分子藥物的批准
      • 傳染病發病率增加，
      • 製藥和生物技術公司增加對先進技術的資本投資，以與 CDMO 建立合作夥伴關係
    • 市場製約因素分析
      • 外包期間的合規問題
      • 新興國家國內情景的變化
  • 大分子 CDMO 市場:分析工具
    • 波特的五力分析
    • PESTEL 分析
    • 對主要交易和戰略聯盟的分析
      • 併購
      • 分機
      • 合同和合作
  • COVID-19 影響和改革分析

第 4 章大分子 CDMO 市場:服務細分分析

  • 大分子 CDMO 市場:定義和範圍
  • 大分子 CDMO 市場:市場份額分析，2022 年和 2030 年
  • 合同製造
    • 臨床
    • 商業
  • 委託開發
    • 細胞系的開發
    • 流程開發

第 5 章大分子 CDMO 市場:供應商細分分析

  • 大分子 CDMO 市場:定義和範圍
  • 大分子 CDMO 市場:市場份額分析，2022 年和 2030 年
  • 哺乳動物
  • 微生物
  • o其他

第 6 章大分子 CDMO 市場:最終用戶細分分析

  • 大分子 CDMO 市場:定義和範圍
  • 大分子 CDMO 市場:市場份額分析，2022 年和 2030 年
  • 生物技術公司
  • 首席風險官
  • 其他（製藥公司、政府、研究機構、學術機構等）

第 7 章大分子 CDMO 市場:區域分析

  • 區域市場概況
  • 大分子 CDMO 市場:市場份額分析，2022 年和 2030 年
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
    • 亞太地區的其他國家/地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 母馬
    • 南非
    • 沙特阿拉伯
    • 你
    • 科威特
    • MEA 的剩餘部分

第8章公司簡介

  • Thermo Fisher Scientific Inc.
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 歐陸科學
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 藥明生物
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 三星生物製品
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 康泰倫特公司
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • Rentschler Biopharma SE
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • AGC 生物製劑
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • Recipharm AB（公共）
    • 公司概況
    • 財務業績
    • 服務基準
  • 齊格弗裡德控股公司
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 勃林格殷格翰
    • 公司概況
    • 服務基準
    • 戰略舉措
  • FUJIFILM Diosynth Biotechnologies
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
Product Code: GVR-4-68039-946-2

Large Molecule Drug Substance CDMO Market Growth & Trends:

The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.3% from 2023 to 2030. Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.

Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities. Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.

Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Large Molecule Drug Substance CDMO Market Report Highlights:

  • The contract manufacturing service segment dominated the market with a revenue share of over 65.0% in 2022
  • Based on source, the mammalian segment accounted for the largest share of over 55.0% in 2022. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody-drug conjugates are evolved
  • Based on end-user, the biotech companies segment accounted for the largest share of over 40.0% in 2022. Rising R&D investment by the firms for large molecules drives the market
  • Asia Pacific is projected to register the fastest CAGR of 10.4% during the forecast period. The large patient base, lower overall costs, skilled workforce, and changes in the regulatory scenario are the key factors driving the market

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 service
    • 1.1.2 Source
    • 1.1.3 End-User
    • 1.1.4 Regional Scope
    • 1.1.5 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data For Primary Interviews In North America
      • 1.3.5.2 Data For Primary Interviews In Europe
      • 1.3.5.3 Data For Primary Interviews In Asia Pacific
      • 1.3.5.4 Data For Primary Interviews In Latin America
      • 1.3.5.5 Data For Primary Interviews In Mea
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume Price Analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Large Molecule Drug Substance CDMO Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Market Variable Analysis
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Increasing large molecule drug approvals
      • 3.2.1.2 Rising incidence of infectious diseases,
      • 3.2.1.3 Higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Compliance issues while outsourcing
      • 3.2.2.2 Changing scenarios within developing countries
  • 3.3 Large Molecule Drug Substance CDMO Market: Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestel Analysis
    • 3.3.3 Major Deals & Strategic Alliances Analysis
      • 3.3.3.1 Mergers And Acquisitions
      • 3.3.3.2 Expansions
      • 3.3.3.3 Agreement & Collaborations
  • 3.4 Covid-19 Impact and Reformation Analysis

Chapter 4 Large Molecule Drug Substance CDMO Market: Service Segment Analysis

  • 4.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 4.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 4.3 contract Manufacturing
    • 4.3.1 Contract Manufacturing Services Market, 2018 - 2030 (USD Million)
    • 4.3.2 Clinical
      • 4.3.2.1 Clinical, 2018 - 2030 (USD Million)
    • 4.3.3 commercial
      • 4.3.3.1 Commercial market, 2018 - 2030 (USD Million)
  • 4.4 Contract Development
    • 4.4.1 Contract Development Market, 2018 - 2030 (USD Million)
    • 4.4.2 Cell Line Development
      • 4.4.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
    • 4.4.3 Process Development
      • 4.4.3.1 Process Development Market, 2018 - 2030 (USD Million)

Chapter 5 Large Molecule Drug Substance CDMO Market: Source Segment Analysis

  • 5.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 5.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 5.3 Mammalian
    • 5.3.1 Mammalian Market, 2018 - 2030 (USD Million)
  • 5.4 Microbial
    • 5.4.1 Microbial Market, 2018 - 2030 (USD Million)
  • 5.5 oOthers
    • 5.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Large Molecule Drug Substance CDMO Market: End-user Segment Analysis

  • 6.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 6.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 6.3 Biotech Companies
    • 6.3.1 Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.4 CRO
    • 6.4.1 CRO Market, 2018 - 2030 (USD Million)
  • 6.5 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.)
    • 6.5.1 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.) Market, 2018 - 2030 (USD Million)

Chapter 7 Large Molecule Drug Substance CDMO Market: Regional Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 Large Molecule Drug Substance Cdmo Market: Market Share Analysis, 2022 & 2030
  • 7.3 North America
    • 7.3.1 North America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.3.2 U.S.
      • 7.3.2.1 U.S. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.3.3 Canada
      • 7.3.3.1 Canada Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.4 Europe
    • 7.4.1 Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.2 U.K.
      • 7.4.2.1 U.K. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.3 Germany
      • 7.4.3.1 Germany Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.4 France
      • 7.4.4.1 France Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.5 Italy
      • 7.4.5.1 Italy Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.6 Spain
      • 7.4.6.1 Spain Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.7 Denmark
      • 7.4.7.1 Denmark Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.8 Sweden
      • 7.4.8.1 Sweden Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.9 Norway
      • 7.4.9.1 Norway Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.10 Rest Of Europe
      • 7.4.10.1rest Of Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.5 Asia Pacific
    • 7.5.1 Asia Pacific Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.2 Japan
      • 7.5.2.1 Japan Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.3 China
      • 7.5.3.1 China Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.4 India
      • 7.5.4.1 India Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.5 Australia
      • 7.5.5.1 Australia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.6 Thailand
      • 7.5.6.1 Thailand Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.7 South Korea
      • 7.5.7.1 South Korea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.8 Rest Of Apac
      • 7.5.8.1 Rest Of Apac Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.6 Latin America
    • 7.6.1 Latin America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.2 Brazil
      • 7.6.2.1 Brazil Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.3 Mexico
      • 7.6.3.1 Mexico Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.4 Argentina
      • 7.6.4.1 Argentina Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.5 Rest Of Latam
      • 7.6.5.1 Rest Of Latam Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.7 Mea
    • 7.7.1 Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.2 South Africa
      • 7.7.2.1 South Africa Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.3 Saudi Arabia
      • 7.7.3.1 Saudi Arabia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Uae
      • 7.7.4.1 Uae Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Kuwait
      • 7.7.4.1 Kuwait Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Rest Of MEA
      • 7.7.4.1 rest Of Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles

    • 8.1.1 Thermo Fisher Scientific Inc.
      • 8.1.1.1 Company Overview
      • 8.1.1.2 Financial Performance
      • 8.1.1.3 Service Benchmarking
      • 8.1.1.4 Strategic Initiatives
    • 8.1.2 Eurofins Scientific
      • 8.1.2.1 Company Overview
      • 8.1.2.2 Financial Performance
      • 8.1.2.3 Service Benchmarking
      • 8.1.2.4 Strategic Initiatives
    • 8.1.3 WuXi Biologics
      • 8.1.3.1 Company Overview
      • 8.1.3.2 Financial Performance
      • 8.1.3.3 Service Benchmarking
      • 8.1.3.4 Strategic Initiatives
    • 8.1.4 Samsung Biologics
      • 8.1.4.1 Company Overview
      • 8.1.4.2 Financial Performance
      • 8.1.4.3 Service Benchmarking
      • 8.1.4.4 Strategic Initiatives
    • 8.1.5 Catalent, Inc.
      • 8.1.5.1 Company Overview
      • 8.1.5.2 Financial Performance
      • 8.1.5.3 Service Benchmarking
      • 8.1.5.4 Strategic Initiatives
    • 8.1.6 Rentschler Biopharma SE
      • 8.1.6.1 Company Overview
      • 8.1.6.2 Financial Performance
      • 8.1.6.3 Service Benchmarking
      • 8.1.6.4 strategic Initiatives
    • 8.1.7 AGC Biologics
      • 8.1.7.1 Company Overview
      • 8.1.7.2 Financial Performance
      • 8.1.7.3 Service Benchmarking
      • 8.1.7.4 Strategic Initiatives
    • 8.1.8 Recipharm AB (publ)
      • 8.1.8.1 Company Overview
      • 8.1.8.2 Financial Performance
      • 8.1.8.3 Service Benchmarking
    • 8.1.8 Siegfried Holding AG
      • 8.1.8.1 Company Overview
      • 8.1.8.2 Financial Performance
      • 8.1.8.3 Service Benchmarking
      • 8.1.8.4 Strategic Initiatives
    • 8.1.10 Boehringer Ingelheim
      • 8.1.10.1 Company Overview
      • 8.1.10.2 Service Benchmarking
      • 8.1.10.3 Strategic Initiatives
    • 8.1.11 FUJIFILM Diosynth Biotechnologies
      • 8.1.11.1 Company Overview
      • 8.1.11.2 Financial Performance
      • 8.1.11.3 Service Benchmarking
      • 8.1.11.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Commodity Flow Analysis
  • Fig. 14 Volume Price Analysis
  • Fig. 15 Large Molecule Drug Substance CDMO market snapshot (2022)
  • Fig. 16 Large Molecule Drug Substance CDMO market segmentation
  • Fig. 17 Large Molecule Drug Substance CDMO market: Strategy framework
  • Fig. 18 Parent market outlook
  • Fig. 19 Related/ancillary market outlook
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 25 Large Molecule Drug Substance CDMO market service outlook: Segment Dashboard
  • Fig. 26 Large Molecule Drug Substance CDMO market: Service movement analysis
  • Fig. 27 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 28 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 29 Commercial market, 2018 - 2030 (USD Million)
  • Fig. 30 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 31 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 32 Process Development market, 2018 - 2030 (USD Million)
  • Fig. 33 35 Large Molecule Drug Substance CDMO market source outlook: Segment Dashboard
  • Fig. 34 Large Molecule Drug Substance CDMO market: Source movement analysis
  • Fig. 35 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 36 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Large Molecule Drug Substance CDMO market end-user outlook: Segment Dashboard
  • Fig. 39 Large Molecule Drug Substance CDMO market: End-User movement analysis
  • Fig. 40 Biotech Companies market, 2018 - 2030 (USD Million)
  • Fig. 41 CRO market, 2018 - 2030 (USD Million)
  • Fig. 42 Others (Pharma companies, Government, Research Institutes, Academic Institutes, Etc
  • Fig. 43 Regional market place: Dashboard
  • Fig. 44 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • Fig. 45 Regional Market Snapshot (Figures in USD Million, 2022)
  • Fig. 46 Regional Market Share, 2022 (USD Million)
  • Fig. 47 Regional outlook, 2022& 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 53 Germany market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan market, 2018 - 2030 (USD Million)
  • Fig. 62 China market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million)